SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of ...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE)-- BioAtla, Inc. (NASDAQ: BCAB or the "Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...

BioAtla (NASDAQ:BCAB) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints for the OSV registrational study in second-line plus oropharyngeal squamous cell carcinoma ...

BioAtla develops precision antibody therapies to treat solid tumors. Its central technology, known as Conditionally Active Biologic (CAB), designs antibodies that become active in the acidic ...

BioAtla (NASDAQ:BCAB) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports.

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement ...

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with ...